Navigation Links
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy

Data Also Show Nebivolol Lowers Blood Pressure in Obese and Non-Obese Hypertensive Patients

CHICAGO, May 21, 2007 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. today presented positive data from two clinical studies and one pooled analysis of nebivolol, a selective beta 1-blocker with vasodilating properties currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension. Data from the two clinical studies show that nebivolol demonstrates blood pressure lowering effects as long-term therapy either alone or in combination with other agents, and also as part of a combination treatment for hypertension. The pooled analysis of three registration monotherapy trials supports nebivolol's blood pressure lowering effects for the treatment of hypertension in obese individuals, a difficult- to-treat patient population. The data were presented at the American Society of Hypertension, Inc. (ASH) 22nd Annual Scientific Meeting and Exposition (ASH 2007) in Chicago.

    


    Data presented at ASH includes:


    -- "Long-Term Exposure to the Novel Beta-Blocker Nebivolol as Monotherapy

       or Combination Therapy: Antihypertensive Efficacy and Safety" by

       Vasilios Papademetriou, MD, Professor of Medicine, Georgetown

       University.  [Poster Presentation, P-419: Monday, May 21 from 12 pm to

       1 pm (Riverside Hall)]


       The long-term treatment effects of nebivolol were evaluated in a

       multicenter, 9-month extension study (n=845) of patients who

       successfully completed one of the three randomized, double-blind,

       placebo-controlled registration studies.  Patients received nebivolol

       monotherapy (5 mg, 10 mg, or 20 mg once daily) or nebivolol plus

       adjunct therapy (open-label diuretics or amlodipine).  Outcomes

       demonstrated that nebivolol treatment produced sustained blood pressure

       reductions for the duration of the study period and was well tolerated


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... The ophthalmic therapeutics company Xcovery Vision announced today that ... Ken Mandell, President and COO, will be speaking at ... Annual Meeting in Fort Lauderdale Florida, May 1-5, 2011. ... recounts his repeated success as founder of multiple ...
... Accuracy in radiation therapy demands careful targeting and ... Farber Center for Radiation Oncology , the first and ... is among the first treatment centers to adopt Elekta,s ... patient positioning system that enables clinicians to fine-tune ...
Cached Medicine Technology:Xcovery Vision Founders to Speak at ARVO 2011 2Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer 2
(Date:4/24/2014)... terminology, and the relevance of palliation in advanced ... randomized controlled trials (RCTs). This is the result ... Quality and Efficiency in Health Care (IQWiG), which ... Together with external experts, IQWiG analysed studies on ... malignant melanoma, and pancreatic cancer. For this purpose, ...
(Date:4/24/2014)... awarded one of 30 grants from the National Cancer ... Site in its new National Clinical Trials Network ... of investigators charged with distributing resources in a more ... system reflects recommendations from a 2010 Institute of ... goals:, Faster design, launch, and completion of ...
(Date:4/23/2014)... by Massachusetts General Hospital (MGH) investigators may lead to ... a serious medical problem use of fecal material ... the Clostridium difficile ( C. difficile ) ... the journal Clinical Infectious Diseases , the researchers ... donors unrelated to patients was as successful in curing ...
(Date:4/23/2014)... J. O,Shea, M.D., scientific director at the National Institute ... been named the 2014 recipient of the Ross Prize ... open-access journal Molecular Medicine . The award will ... Academy of Sciences in Manhattan, followed by scientific presentations ... part of the National Institutes of Health. , The ...
(Date:4/23/2014)... researchers have identified an important enzyme pathway that helps ... few chromosomes, a condition that has been directly linked ... professor of biochemistry, found that near the end of ... that ensures any breaks in DNA are fully repaired ... to daughter cells. This process helps safeguard against some ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... of herbal products and medicines has the potential to reach ... the creation of exclusive export promotion zones (EPZ) across ... can be accelerated with the setting up of EPZs in ... rate of over 25 percent in countries like the US, ...
... as marijuana or ganja, can help in the treatment ... body tissues are attacked by its own immune system. ... University of Bonn, used tetrahydrocannabinol (THC), the active ingredient ... that it reduced skin allergies. ,However, the ...
... Today at the 61st Annual Meeting of the ... Cordis Corporation, announced the worldwide launch of the ... use in angioplasty procedures for patients with carotid ... a unique high-pressure expansion and low profile .014 ...
... better way to say "I love you" than showing your Dad ... come . This Father's Day, the American Diabetes Association (ADA) wants ... out by their doctor. ,More than 10 percent of all ... 2 diabetes, the most common form of the disease, can come ...
... number of suicide attempts among asylum seekers in Denmark has ... of despair," according to a study published Thursday . ... camps -- or 0.6 percent of the total -- tried ... by the Danish Association to Help Refugees said. ...
... for a new study has found that regular practice ... as well as the cognitive decline associated with ... practice, is centred on attentional and postural self-regulation and ... normal age-related decline of cerebral gray matter volume and ...
Cached Medicine News:Health News:Export of Herbal Products to Reach Rs.120 Billion by 2012: Study 2Health News:New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty 2Health News:Drag Dad to the Doctor This Father's Day 2
... Aestiva/5 Pendant anesthesia machine offers proven ... range with the SmartVent ventilator. However, ... superior ventilation. Enhancements in flexibility, ergonomics ... in anesthesia delivery., ,The Aestiva/5 ...
With its integrated design and superior build quality each Prima SP is custom built to meet your requirements....
... Tegagel hydrogel wound filler and ... are amorphous hydrogel dressings specially formulated ... that has been shown to enhance ... formula meets clinical needs for management ...
Features various cylinder sizes and a simple two-handed pumping mechanism....
Medicine Products: